DIPNA PHARMACHEM LIMITED (DPL) reported revenue of ₹2.02 Cr and net profit of ₹17.86 L for the quarter ended 2026-03-31. Figures are parsed from the company's filed results.
DPL fundamentals, Fundamental score 61/100
The statements below are read from DIPNA PHARMACHEM LIMITED’s filed results, 1 filed quarter and 9 fiscal years on record, standalone basis. Price-linked ratios are computed at the last close, sector medians across the served universe, ownership from the shareholding pattern, and any cell whose input isn’t on record shows a dash, never an estimate.
Latest: Q4 FY25-26 · filed Jul 3, 2026 · audited
Sales CAGR · 3Y+8.9%FY22 → FY25
Sales CAGR · 4Y+15.3%FY21 → FY25
PAT CAGR · 3Y+38.1%FY22 → FY25
PAT CAGR · 4Y+27.4%FY21 → FY25
Price · 1Y—EOD
Price CAGR · 3Y—EOD
Quarterly resultsStandalone
₹ Cr
Mar2026Latest
YoYlatest
Sales
2.02
—
1.59
—
Operating profit
0.43
—
OPM %
21.4%
—
Other income
0.03
—
Interest
0.23
—
Depreciation
0.00
—
Profit before tax
0.22
—
Tax %
19.8%
—
Net profit
0.18
—
EPS (₹)
0.07
—
One column per filed quarter · ₹ crore · YoY = latest vs the same quarter a year back · EPS restated for bonus/split↔ scroll for earlier quarters
Segment results
Needs segment dataSegment results not parsedPer-segment revenue, EBIT margin and YoY arrive once we parse the segment annexure from the filing.
Forensic checksauto-scanned from the filing
Coming soonForensic checks not connectedAuditor opinion, OCF÷PAT, contingent liabilities, related-party share and working-capital days arrive as we parse the notes-to-accounts + cash-flow statement. Promoter-pledge is already on the Holdings tab.
How results moved the priceEOD reaction on the session the market could trade the filing
Avg absolute result-day move ±2.0%· EPS surprise: no estimates source
